CDH1/E-cadherin：從黏附調(diào)控到腫瘤靶向治療的核心靶點(diǎn)研究進(jìn)展
日期：2026-03-17 08:52:24
E-cadherin由CDH1基因編碼，是上皮細(xì)胞鈣依賴性黏附分子，在維持上皮結(jié)構(gòu)完整性、細(xì)胞間通訊與組織穩(wěn)態(tài)中處于核心地位 [1,2]。CDH1功能受損常導(dǎo)致細(xì)胞間黏附松解并觸發(fā)上皮-間充質(zhì)轉(zhuǎn)化（EMT）等關(guān)鍵表型變化，是多種腫瘤發(fā)生發(fā)展的重要驅(qū)動(dòng)因素 [3]。本文圍繞CDH1的結(jié)構(gòu)與生理功能、多層次調(diào)控、關(guān)鍵通路、疾病譜和靶向藥物最新研究進(jìn)展進(jìn)行結(jié)構(gòu)化梳理，以期為您的研究帶來(lái)幫助。
1. 背景與研究意義：CDH1為何是“黏附—信號(hào)—疾病”樞紐
2. CDH1/E-cadherin的結(jié)構(gòu)與細(xì)胞-細(xì)胞黏附：從分子裝配到力學(xué)耦聯(lián)
3. 多層次調(diào)控機(jī)制：決定E-cadherin“表達(dá)水平與功能狀態(tài)”的關(guān)鍵環(huán)節(jié)
4. 關(guān)鍵信號(hào)通路與細(xì)胞表型：從EMT到微環(huán)境適應(yīng)
1. 背景與研究意義：CDH1為何是“黏附—信號(hào)—疾病”樞紐
E-cadherin通過(guò)形成黏附連接（adherens junctions）將相鄰細(xì)胞機(jī)械耦聯(lián)，并與肌動(dòng)蛋白骨架連接，參與細(xì)胞遷移、分化與信號(hào)轉(zhuǎn)導(dǎo) [2]。因此，E-cadherin通常被視為重要腫瘤抑制因子，其缺失可削弱細(xì)胞黏附并促進(jìn)侵襲轉(zhuǎn)移 [3]。除宏觀組織結(jié)構(gòu)外，E-cadherin還參與更精細(xì)的空間組織：在角質(zhì)形成細(xì)胞中，E-cadherin缺失可造成微尺度細(xì)胞分離（micro-demixing），提示黏附在微觀組織均質(zhì)性/模式形成中具有“精細(xì)調(diào)參”作用 [4]。
臨床上，CDH1致病性生殖系突變與遺傳性彌漫性胃癌（HDGC）高度相關(guān)，攜帶者具有顯著升高的彌漫性胃癌終生風(fēng)險(xiǎn) [5-9]，并且在特定人群（如新西蘭毛利人）中被證實(shí)是早發(fā)彌漫性胃癌高發(fā)的重要遺傳因素 [5]。除編碼區(qū)突變外，下游調(diào)控序列缺失（如CDH1-TANGO6缺失）也可顯著下調(diào)CDH1表達(dá)并導(dǎo)致極早發(fā)、高外顯率的彌漫性胃癌 [10]；在散發(fā)性胃癌中，CDH1遺傳變異與表觀遺傳改變（如啟動(dòng)子甲基化）同樣與致癌過(guò)程密切相關(guān) [11]。此外，彌漫性胃癌中細(xì)胞-細(xì)胞/細(xì)胞-基質(zhì)黏附依賴性的“逃逸”與RHO信號(hào)擾動(dòng)（如RHOA突變或ARHGAP融合）相關(guān)，強(qiáng)調(diào)黏附改變與細(xì)胞內(nèi)信號(hào)重塑存在協(xié)同關(guān)系 [12]。
值得注意的是，CDH1在不同腫瘤背景下可能呈現(xiàn)差異性作用。例如在乳腺癌中，CDH1可出現(xiàn)表達(dá)上調(diào)，并與分期、轉(zhuǎn)移、干細(xì)胞特性及不良預(yù)后相關(guān)，提示其在特定背景下可能呈現(xiàn)促腫瘤效應(yīng) [13]；而在治療選擇有限的三陰性乳腺癌中，CDH1缺陷較為常見，推動(dòng)了“CDH1缺陷型腫瘤”靶向策略的探索 [14]。
2. CDH1/E-cadherin的結(jié)構(gòu)與細(xì)胞-細(xì)胞黏附：從分子裝配到力學(xué)耦聯(lián)
E-cadherin是跨膜糖蛋白，胞外區(qū)由多個(gè)cadherin repeats構(gòu)成，在鈣離子存在下穩(wěn)定并介導(dǎo)同型結(jié)合，是黏附連接形成的基礎(chǔ) [1]。其胞內(nèi)區(qū)與β-catenin等銜接蛋白結(jié)合并連接肌動(dòng)蛋白骨架，從而實(shí)現(xiàn)力學(xué)傳遞與組織尺度的機(jī)械耦聯(lián) [17,2]。相關(guān)生物物理模型將黏附復(fù)合物視作可傳遞阻力/張力的“彈簧樣結(jié)構(gòu)”，能夠解釋細(xì)胞極化、振蕩動(dòng)力學(xué)以及超細(xì)胞應(yīng)力鏈等多細(xì)胞行為，提示“黏附—骨架”并非靜態(tài)連接，而是雙向耦合的動(dòng)力系統(tǒng) [2]。
結(jié)構(gòu)層面的致病變異可直接破壞黏附功能。例如G212E錯(cuò)義突變會(huì)顯著影響E-cadherin穩(wěn)定性、定位與黏附能力，導(dǎo)致組織結(jié)構(gòu)紊亂并削弱抗侵襲性 [19]。此外，E-cadherin功能也受復(fù)雜信號(hào)網(wǎng)絡(luò)調(diào)控：如PAK5可參與維持細(xì)胞-細(xì)胞黏附完整性，提示黏附復(fù)合物并非“結(jié)構(gòu)件”，而是受激酶網(wǎng)絡(luò)持續(xù)調(diào)節(jié)的功能模塊 [20]。
3. 多層次調(diào)控機(jī)制：決定E-cadherin“表達(dá)水平與功能狀態(tài)”的關(guān)鍵環(huán)節(jié)
3.1 遺傳與表觀遺傳調(diào)控
在HDGC及散發(fā)性胃癌中，CDH1可因編碼區(qū)突變、調(diào)控序列缺失或啟動(dòng)子甲基化等機(jī)制導(dǎo)致表達(dá)下降或功能缺失 [5,10,11]。在炎癥背景下，CDH1位點(diǎn)CpG甲基化增加也被報(bào)道與黏膜炎癥相關(guān)聯(lián)，提示慢性炎癥可能通過(guò)表觀遺傳途徑削弱上皮屏障 [24]。此外，乳腺癌中也存在CDH1異常甲基化與表達(dá)缺失的證據(jù) [25]。
3.2 轉(zhuǎn)錄后調(diào)控與非編碼RNA網(wǎng)絡(luò)
多種miRNA/lncRNA被用于解釋CDH1在不同腫瘤中的動(dòng)態(tài)變化。例如，miR-92a-3p在膠質(zhì)瘤及膠質(zhì)瘤干樣細(xì)胞中可通過(guò)靶向CDH1/β-catenin并影響Notch-1/Akt信號(hào)，參與腫瘤表型調(diào)控 [26]；lncRNA SNHG1與hnRNPL形成復(fù)合體并共同調(diào)控CDH1，從而促進(jìn)前列腺癌生長(zhǎng)與轉(zhuǎn)移 [32]。
3.3 翻譯后修飾與蛋白互作
糖基化是影響E-cadherin活性與細(xì)胞行為的重要機(jī)制。在胰腺癌細(xì)胞中，ST3Gal III改變E-cadherin唾液酸化模式并降低細(xì)胞-細(xì)胞聚集能力，同時(shí)增強(qiáng)侵襲遷移相關(guān)信號(hào)（如FAK Tyr397磷酸化），提示“糖鏈-黏附-遷移”之間存在可觀測(cè)的功能鏈條 [22]?；プ鲗用?，MCC蛋白可與E-cadherin及β-catenin互作并增強(qiáng)結(jié)直腸癌細(xì)胞黏附，提示黏附復(fù)合體穩(wěn)定性還依賴腫瘤抑制網(wǎng)絡(luò)的協(xié)同 [21]。
4. 關(guān)鍵信號(hào)通路與細(xì)胞表型：從EMT到微環(huán)境適應(yīng)
CDH1缺陷最典型的后果是EMT相關(guān)表型增強(qiáng)。已有研究提出，SPHK1可通過(guò)促進(jìn)自噬-溶酶體途徑降解CDH1/E-cadherin從而誘導(dǎo)EMT，提示“代謝酶—自噬—黏附降解”的串聯(lián)機(jī)制可能參與肝癌進(jìn)展 [31]。另一方面，CDH1表達(dá)也與代謝重編程存在聯(lián)系：E-cadherin可誘導(dǎo)絲氨酸合成以支持乳腺癌進(jìn)展和轉(zhuǎn)移，提示其在特定背景下可能通過(guò)代謝路徑促進(jìn)腫瘤適應(yīng) [28]。ZHX2缺陷可富集雜合型MET細(xì)胞并通過(guò)調(diào)控E-cadherin表達(dá)影響EMT/MET動(dòng)態(tài)平衡，強(qiáng)調(diào)CDH1并非簡(jiǎn)單“開/關(guān)”，而可能參與多狀態(tài)轉(zhuǎn)換 [33]。
在通路層面，CDH1常與Wnt/β-catenin、PI3K/AKT/mTOR、MAPK/ERK及TGF-β/Smad等網(wǎng)絡(luò)交織。既往研究在食管癌中討論了Wnt/β-catenin與TGF-β-Smad通路的表觀遺傳失調(diào)及其對(duì)預(yù)后的影響 [3]；在結(jié)直腸癌中，WNT通路組分也存在遺傳與表觀遺傳改變并與微衛(wèi)星不穩(wěn)定性分層相關(guān) [30]。
此外，CDH1異常還與上皮屏障破壞相關(guān)：在SARS-CoV-2感染的Caco-2腸上皮模型中，CDH1/E-cadherin表達(dá)與可溶性E-cadherin釋放受到影響，并被討論為腸道表現(xiàn)相關(guān)的潛在生理病理基礎(chǔ)之一 [29]。
5. 相關(guān)疾病：從高外顯率遺傳綜合征到多癌種與炎癥/感染上皮病理
5.1 遺傳性彌漫性胃癌（HDGC）：以CDH1缺陷為核心的高風(fēng)險(xiǎn)疾病譜
HDGC是CDH1研究中最具“遺傳—機(jī)制—臨床管理”閉環(huán)特征的場(chǎng)景?，F(xiàn)有研究強(qiáng)調(diào)：在新西蘭毛利人群中，生殖系CDH1突變被證實(shí)顯著貢獻(xiàn)于早發(fā)彌漫性胃癌的高發(fā)生頻率，提示其在特定遺傳背景/人群結(jié)構(gòu)下具有重要公共衛(wèi)生意義 [5]。除經(jīng)典編碼區(qū)突變外，CDH1及其下游調(diào)控序列的聯(lián)合缺失（CDH1-TANGO6缺失）可造成CDH1表達(dá)顯著下降，并與極早發(fā)且高外顯率彌漫性胃癌相關(guān)，提示“編碼區(qū)之外的調(diào)控區(qū)域”同樣可能決定疾病負(fù)擔(dān) [10]。
在散發(fā)性胃癌中，CDH1相關(guān)的遺傳變異與表觀遺傳改變（例如調(diào)控區(qū)改變與啟動(dòng)子甲基化）被一并討論為影響CDH1表達(dá)與致癌過(guò)程的重要因素，提示HDGC與散發(fā)性胃癌之間并非完全割裂，而可能在機(jī)制上存在“同軸不同強(qiáng)度”的連續(xù)譜 [11]?；谖赴╊惼鞴倌Ｐ偷难芯繌?qiáng)調(diào)，疾病進(jìn)展過(guò)程中可出現(xiàn)對(duì)細(xì)胞-細(xì)胞與細(xì)胞-基質(zhì)黏附依賴性的“逃逸”，并伴隨RHO信號(hào)擾動(dòng)（如RHOA突變或ARHGAP融合）[12]。這類證據(jù)把“CDH1缺陷導(dǎo)致黏附失衡”與“細(xì)胞內(nèi)信號(hào)重塑”連接起來(lái)，為理解彌漫性胃癌的侵襲性生物學(xué)行為提供機(jī)制線索 [12]。
5.2 乳腺癌：CDH1既可能是缺失驅(qū)動(dòng)，也可能呈現(xiàn)情景依賴的“反直覺表達(dá)”
乳腺癌中CDH1呈現(xiàn)更強(qiáng)的異質(zhì)性,CDH1生殖系突變與遺傳性小葉型乳腺癌相關(guān)，被用于討論遺傳性腫瘤風(fēng)險(xiǎn)譜與遺傳咨詢路徑 [9]。此外，家族性乳腺癌風(fēng)險(xiǎn)也被報(bào)道與CDH1等位基因SNP相關(guān)性有關(guān) [27]。在部分研究中，CDH1可能出現(xiàn)表達(dá)上調(diào)，并與分期、轉(zhuǎn)移、干細(xì)胞特性及不良預(yù)后相關(guān)，提示其在某些背景下可能呈現(xiàn)促腫瘤效應(yīng) [13]。這意味著在乳腺癌語(yǔ)境下，不能簡(jiǎn)單用“E-cadherin高=抑癌、低=促癌”概括，其臨床解釋往往需要結(jié)合腫瘤分型與分子網(wǎng)絡(luò) [13]。在三陰性乳腺癌等治療選擇有限場(chǎng)景中，CDH1缺陷更容易被納入“可干預(yù)脆弱性”的討論，并推動(dòng)聯(lián)合抑制策略探索 [14]。
5.3 結(jié)直腸癌：易感基因證據(jù)、黏附復(fù)合體穩(wěn)態(tài)與炎癥相關(guān)腫瘤免疫
結(jié)直腸癌相關(guān)證據(jù)鏈條更偏向“遺傳易感—網(wǎng)絡(luò)穩(wěn)態(tài)—腫瘤免疫背景”,GWAS研究把CDH1納入結(jié)直腸癌遺傳易感基因圖譜，提示其在群體層面具有風(fēng)險(xiǎn)相關(guān)性 [15]。MCC蛋白與E-cadherin/β-catenin互作可增強(qiáng)結(jié)直腸癌細(xì)胞黏附，強(qiáng)調(diào)CDH1相關(guān)表型不僅由單基因決定，也與黏附復(fù)合體伙伴蛋白網(wǎng)絡(luò)有關(guān) [21]。在炎癥性腸病相關(guān)結(jié)直腸癌中，IBD相關(guān)基因被用于預(yù)后與腫瘤免疫含義分析，CDH1亦被納入相關(guān)討論框架 [16]。與此相呼應(yīng)，結(jié)直腸癌中的WNT通路組分改變及其與微衛(wèi)星不穩(wěn)定性分層的關(guān)系，為解釋上皮穩(wěn)定性破壞與信號(hào)重編程提供了宏觀通路層面的背景 [30]。
5.4 食管癌與癌前病變：CDH1/CTNNB1表達(dá)下降與轉(zhuǎn)移、預(yù)后相關(guān)
在食管癌中，CDH1或CTNNB1表達(dá)降低與淋巴結(jié)轉(zhuǎn)移及不良預(yù)后相關(guān)，這一觀察把“黏附復(fù)合體失衡”與更不利的臨床結(jié)局聯(lián)系起來(lái) [17]。同時(shí)，關(guān)于Wnt/β-catenin與TGF-β-Smad通路的表觀遺傳失調(diào)被用于解釋食管癌的預(yù)后差異，提示CDH1改變往往與更大范圍的通路層級(jí)異常并行出現(xiàn) [3]。
在癌前病變層面，口腔扁平苔蘚中EMT相關(guān)蛋白（含E-cadherin）的表達(dá)改變提示細(xì)胞連接紊亂可能與病變演進(jìn)相關(guān)，為“黏附改變的早期提示意義”提供了證據(jù)線索 [18]。
5.5 炎癥與感染相關(guān)上皮屏障：甲基化改變與可溶性E-cadherin釋放
CDH1不僅與腫瘤相關(guān)，也與上皮屏障狀態(tài)密切相關(guān)：在炎癥背景下，CDH1位點(diǎn)CpG甲基化增加與黏膜炎癥相關(guān)聯(lián)，提示慢性炎癥可能通過(guò)表觀遺傳途徑影響上皮黏附與屏障穩(wěn)態(tài) [24]。在SARS-CoV-2感染的Caco-2腸上皮模型中，CDH1/E-cadherin表達(dá)及可溶性E-cadherin釋放發(fā)生變化，被用于討論腸道表現(xiàn)相關(guān)的病理基礎(chǔ)之一 [29]。與檢測(cè)相關(guān)的證據(jù)還包括：尿液中可溶性E-cadherin片段升高被認(rèn)為可能反映上皮腫瘤細(xì)胞的剪切/脫落過(guò)程，為非侵入性標(biāo)志物提供線索 [23]。
6. CDH1靶向藥物最新研究進(jìn)展
目前靶向CDH1的藥物研發(fā)主要處于臨床前及早期發(fā)現(xiàn)階段，涵蓋小分子化藥、生物藥、外泌體等多種類型。主要探索方向包括腦惡性膠質(zhì)瘤、乳腺癌及多囊疾病等，涉及沈陽(yáng)藥科大學(xué)、哈佛大學(xué)、四川省腫瘤醫(yī)院等多家機(jī)構(gòu)。
| 藥物 | 類型 | 適應(yīng)癥 | 研發(fā)階段 | 研發(fā)機(jī)構(gòu) |
|---|---|---|---|---|
| AL-GDa62 | 小分子抑制劑 | CDH1缺陷型胃癌 | 臨床前 | 新西蘭奧塔哥大學(xué) |
| Dasatinib | 多激酶抑制劑 | CDH1缺陷型腫瘤 | 臨床前 | 多個(gè)研究機(jī)構(gòu) |
| FAK抑制劑 + ROS1抑制劑 | 聯(lián)合療法 | CDH1缺陷型癌癥 | 臨床前 | 多個(gè)研究機(jī)構(gòu) |
| 外泌體遞送CDH1 mRNA | 基因治療 | 上皮屏障損傷修復(fù) | 探索階段 | 國(guó)內(nèi)科研機(jī)構(gòu) |
7. CDH1研究工具推薦：重組蛋白、抗體與ELISA試劑盒選型指南
華美生物提供CDH1重組蛋白、抗體及ELISA試劑盒產(chǎn)品，助力您進(jìn)行相關(guān)機(jī)制研究及靶向藥物開發(fā)。
[1] Anna Zhigun, Mabel Lizzy Rajendran.(2023). Modelling non-local cell-cell adhesion: a multiscale approach.
[2] XinXin Du, Ido Lavi, Michael J. Shelley.(2025). Collective multicellular patterns arising from cadherin-linked cytoskeletal domains.
[3] Virendra Singh, A. Singh, I. Sharma, L. Singh, J. Sharma, B. B. Borthakar, A. Rai, A. Kataki, S. Kapur, S. Saxena.(2019). Epigenetic deregulations of Wnt/β-catenin and transforming growth factor beta-Smad pathways in esophageal cancer: Outcome of DNA methylation.
[4] Preeti Sahu, Daniel M. Sussman, Matthias Rubsam, Aaron F. Mertz, Valerie Horsley, Eric R. Dufresne, Carien M. Niessen, M. Cristina Marchetti, M. Lisa Manning, J. M. Schwarz.(2019). Small-scale demixing in confluent biological tissues.
[5] C. Hakkaart, L. Ellison-Loschmann, R. Day, A. Sporle, Jonathan Koea, Pauline Harawira, Soo Cheng, M. Gray, Tracey Whaanga, N. Pearce, P. Guilford.(2018). Germline CDH1 mutations are a significant contributor to the high frequency of early-onset diffuse gastric cancer cases in New Zealand Māori.
[6] I. Chen, Lesley Mathews-Greiner, Dandan Li, A. Abisoye-Ogunniyan, Satyajit Ray, Yansong Bian, V. Shukla, Xiaohu Zhang, Rajarashi Guha, Craig J. Thomas, B. Gryder, A. Zacharia, J. Beane, S. Ravichandran, M. Ferrer, U. Rudloff.(2017). Transcriptomic profiling and quantitative high-throughput (qHTS) drug screening of CDH1 deficient hereditary diffuse gastric cancer (HDGC) cells identify treatment leads for familial gastric cancer.
[7] Nicola Bougen-Zhukov, Lyvianne Decourtye-Espiard, Wilson Mitchell, Kieran Redpath, J. Perkinson, T. Godwin, M. Black, P. Guilford.(2022). E-Cadherin-Deficient Cells Are Sensitive to the Multikinase Inhibitor Dasatinib.
[8] T. Godwin, S. Kelly, Tom Brew, Nicola Bougen-Zhukov, A. Single, Augustine Chen, Cassie E Stylianou, L. Harris, Sophie K Currie, Bryony J. Telford, Henry Beetham, G. Evans, M. Black, P. Guilford.(2018). E-cadherin-deficient cells have synthetic lethal vulnerabilities in plasma membrane organisation, dynamics and function.
[9] G. Corso, M. Intra, C. Trentin, P. Veronesi, V. Galimberti.(2016). CDH1 germline mutations and hereditary lobular breast cancer.
[10] C. São José, J. Garcia-Pelaez, Marta Ferreira, O. Arrieta, Ana André, Nelson Martins, Samantha Solís, B. Martínez-Benítez, M. Ordoñez-Sánchez, M. Rodríguez-Torres, Anna K. Sommer, Iris B A W Te Paske, C. Caldas, M. Tischkowitz, María Teresa Tusié, Stefan Gabriel Sérgio Richarda M. Gareth Susana José Luzi Aretz Capella Castedo de Voer Evans Fernandes Garc, S. Aretz, G. Capellá, S. Castedo, Richarda M. de Voer, Gareth Evans, Susana Fernandes, J. Garcia-Pelaez, L. Garrido, E. Holinski-Feder, N. Hoogerbrugge, D. Huntsman, A. Jahn, C. Kets, A. Laner, M. Ligtenberg, Andrea Meinhardt, A. Mensenkamp, Carla Oliveira, S. Peters, I. Quintana, E. Schröck, Anna K. Sommer, I. Spier, L. Spruijt, V. Steinke-Lange, I. T. Paske, M. Tischkowitz, L. Valle, R. S. van der Post, Y. V. van Herwaarden, W. V. van Zelst-Stams, D. William, N. Hoogerbrugge, German Demidov, Richarda M. de Voer, S. Laurie, Carla Oliveira.(2023). Combined loss of CDH1 and downstream regulatory sequences drive early-onset diffuse gastric cancer and increase penetrance of hereditary diffuse gastric cancer.
[11] G. Tedaldi, C. Molinari, C. São José, Rita Barbosa-Matos, A. André, R. Danesi, V. Arcangeli, M. Ravegnani, L. Saragoni, P. Morgagni, F. Rebuzzi, M. Canale, S. Pignatta, Elisa Ferracci, G. Martinelli, G. Ranzani, Carla Oliveira, D. Calistri, P. Ulivi.(2021). Genetic and Epigenetic Alterations of CDH1 Regulatory Regions in Hereditary and Sporadic Gastric Cancer.
[12] Yin Tong, P. Cheng, Chung Sze Or, Sarah S K Yue, H. Siu, S. Ho, S. Law, W. Tsui, D. Chan, Stephanie Ma, Siu Po Lee, Annie S. Y. Chan, April S Chan, Shui Wa Yun, Ho Sang Hui, S. Yuen, S. Leung, Helen H. N. Yan.(2022). Escape from cell-cell and cell-matrix adhesion dependence underscores disease progression in gastric cancer organoid models.
[13] D. Xie, Yiyu Chen, Xue Wan, Jingyuan Li, Qin Pei, Yanan Luo, Jinbo Liu, Ting Ye.(2022). The Potential Role of CDH1 as an Oncogene Combined With Related miRNAs and Their Diagnostic Value in Breast Cancer.
[14] Jiaming Gao, Yunying Yao, Zaiqi Wang, Baoyuan Zhang, R. Ren.(2023). Abstract 5821: Synergism of FAK and ROS1 inhibitors in the treatment of CDH1-deficient cancers mediated by FAK-YAP-TRX signaling.
[15] Da-Tian Bau, Ting-Yuan Liu, Jai-Sing Yang, William Tzu-Liang Chen, Chia‐Wen Tsai, Wen‐Shin Chang, Tao-Wei Ke, Chi-Chou Liao, Yu-Chia Chen, Yen-Ting Chang, Fuu-Jen Tsai.(2024). Characterizing Genetic Susceptibility to Colorectal Cancer in Taiwan Through Genome‐Wide Association Study.
[16] Di Wang, Biao Xie.(2022). Prognostic and tumor immunity implication of inflammatory bowel disease-associated genes in colorectal cancer.
[17] H. Ishiguro, T. Wakasugi, Yukio Terashita, N. Sakamoto, Tatsuya Tanaka, K. Mizoguchi, H. Sagawa, T. Okubo, H. Takeyama.(2016). Decreased expression of CDH1 or CTNNB1 affects poor prognosis of patients with esophageal cancer.
[18] L. Hämäläinen, Y. Soini, S. Pasonen-Seppänen, M. Siponen.(2019). Alterations in the expression of EMT-related proteins claudin-1, -4 and -7, E-cadherin, TWIST1 and ZEB1 in oral lichen planus..
[19] J. Figueiredo, F. Mercadillo, Soraia Melo, A. Barroso, Margarida Gonçalves, J. Diaz-Tasende, Patrícia Carneiro, L. Robles, F. Colina, C. Ibarrola, J. Perea, Eurico Morais-de-Sá, R. Seruca, M. Urioste.(2021). Germline CDH1 G212E Missense Variant: Combining Clinical, In Vitro and In Vivo Strategies to Unravel Disease Burden.
[20] A. F. Ismail, Sevil Oskay Halacli, N. Babteen, M. De Piano, T. Martin, W. Jiang, Muhammad S. Khan, P. Dasgupta, C. Wells.(2017). PAK5 mediates cell: cell adhesion integrity via interaction with E-cadherin in bladder cancer cells..
[21] F. Benthani, F. Benthani, D. Herrmann, D. Herrmann, P. N. Tran, P. N. Tran, L. Pangon, L. Pangon, M. Lucas, A. Allam, N. Currey, S. Al‐Sohaily, Marc Giry-Laterrière, J. Warusavitarne, P. Timpson, P. Timpson, M. R. Kohonen-Corish, M. R. Kohonen-Corish, M. R. Kohonen-Corish.(2018). ‘MCC’ protein interacts with E-cadherin and β-catenin strengthening cell–cell adhesion of HCT116 colon cancer cells.
[22] Sònia Bassagañas, S. Carvalho, A. M. Dias, Marta Pérez-Garay, M. R. Ortiz, J. Figueras, C. Reis, S. Pinho, R. Peracaula.(2014). Pancreatic Cancer Cell Glycosylation Regulates Cell Adhesion and Invasion through the Modulation of α2β1 Integrin and E-Cadherin Function.
[23] M. Katayama, S. Hirai, M. Yasumoto, K. Nishikawa, S. Nagata, M. Otsuka, K. Kamihagi, I. Kato.(1994). Soluble fragments of e-cadherin cell-adhesion molecule increase in urinary-excretion of cancer-patients, potentially indicating its shedding from epithelial tumor-cells..
[24] Charles de Ponthaud, Solafah Abdalla, M. Belot, Xiaojian Shao, Christophe Penna, A. Brouquet, Pierre Bougnères.(2024). Increased CpG methylation at the CDH1 locus in inflamed ileal mucosa of patients with Crohn disease.
[25] Asia Asiaf, S. T. Ahmad, S. Aziz, A. Malik, Zubaida Rasool, A. Masood, M. Zargar.(2014). Loss of expression and aberrant methylation of the CDH1 (E-cadherin) gene in breast cancer patients from Kashmir..
[26] Hang Song, Yao-quan Zhang, Na Liu, Sheng Zhao, Y. Kong, Liudi Yuan.(2016). miR-92a-3p Exerts Various Effects in Glioma and Glioma Stem-Like Cells Specifically Targeting CDH1/β-Catenin and Notch-1/Akt Signaling Pathways.
[27] M. Bagherpour, Kamelia Gharibzad, H. Rassi.(2018). Association of CDH1 and TERT Single-Nucleotide Polymorphisms with Susceptibility to Familial Breast Cancer Risk..
[28] Geonhui Lee, Claudia Wong, Anna Cho, Junior J West, Ashleigh J. Crawford, Gabriella C. Russo, B. R. Si, Jungwoo Kim, Lauren Hoffner, Cholsoon Jang, Moonjung Jung, Robert D Leone, K. Konstantopoulos, Andrew J Ewald, Denis Wirtz, Sangmoo Jeong.(2024). E-cadherin Induces Serine Synthesis to Support Progression and Metastasis of Breast Cancer..
[29] I. O. Osman, Clémence Garrec, Gabriel Augusto Pires de Souza, A. Zarubica, Djamal Brahim Belhaouari, J. Baudoin, H. Lepidi, J. Mege, B. Malissen, B. Scola, C. Devaux.(2022). Control of CDH1/E-Cadherin Gene Expression and Release of a Soluble Form of E-Cadherin in SARS-CoV-2 Infected Caco-2 Intestinal Cells: Physiopathological Consequences for the Intestinal Forms of COVID-19.
[30] L. Thorstensen, G. E. Lind, T. Løvig, C. B. Diep, G. Meling, T. Rognum, R. Lothe.(2005). Genetic and epigenetic changes of components affecting the WNT pathway in colorectal carcinomas stratified by microsatellite instability..
[31] Hong Liu, Yan Ma, Hong-wei He, Wu-li Zhao, R. Shao.(2017). SPHK1 (sphingosine kinase 1) induces epithelial-mesenchymal transition by promoting the autophagy-linked lysosomal degradation of CDH1/E-cadherin in hepatoma cells.
[32] Xiao Tan, Wenbin Chen, D. Lv, Tao-wei Yang, Kai-hui Wu, Li-bin Zou, Junqi Luo, Xu-min Zhou, Guo-chang Liu, F. Shu, X. Mao.(2020). LncRNA SNHG1 and RNA binding protein hnRNPL form a complex and coregulate CDH1 to boost the growth and metastasis of prostate cancer.
[33] Yan He, Qimin Zhang, Yuan-Xiao Chen, Yingjian Wu, Yuan Quan, Weihua Chen, Jing Yao, Peijing Zhang.(2023). ZHX2 deficiency enriches hybrid MET cells through regulating E-cadherin expression.
